Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná

Abstract

ObjectiveThe aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile.MethodsThe overall survival and disease-free survival were statistically evaluated using the Kaplan–Meier method, the log-rank test and multivariate evaluation by Cox regression analysis.ResultsThe study population was predominantly younger than 60 years old (81,6%), had intermediate cytogenetic risk (40.8%), in first complete remission after induction chemotherapy (46.9%), with a white blood count at diagnosis of less than 30 × 109/L (57.1%) and de novo acute myeloid leukemia (62.2%). Survival curves showed that better prognosis was related to age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good prognostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and white blood cell count at diagnosis of less than 30 × 109/L (median survival: 23.6 months; p-value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4 months for M4, M5, M6, and M7 (p-value = 0.0288).ConclusionPrognostic factors strongly influenced patient survival, as well as guided treatment. Moreover, these factors were consistent with the available literature adjusted for the population in question.

Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients

“…Our results proved that higher number of WBCs was significantly associated with shorter EFS and OS and this came in agreement with other studies [ 26 ]. This significant negative correlation between higher WBC counts and reduced OS and DFS could be explained partly by the fact that high WBC counts were associated with an increased risk of tumor lysis syndrome and leukostasis and both were considered oncologic emergencies and subsequently affected the prognosis of patients [ 27 ].…”

Geographic Hematology: Some Observations in Mexico

“…The median age at diagnosis in Latin American countries or developing countries is very similar to ours. Brazil has reported a median age at diagnosis of 33-44 years [27,28], and for other low-middle-income countries such as India and Malaysia the median age of patients with AML has been observed to be 40 and 39 years, respectively [29,30]. The exact cause of this age difference is unclear.…”

Prognostic Factors, Survival Analysis and Cytogenetic Outcomes in Adult Patients with Acute Myeloid Leukemia: A single Center Results

“…11 t(8.21), inv (16), and t(16;16) stand for good cytogenetic risk characteristics. 7 In systemic reviews and meta-analyses, it was found that FLT3-ITD mutation is associated with poor prognosis, whereas NPMI1 and CEPBA mutations are associated with good prognosis.…”

“…15 In the study by Padilha et al, 40.8% of the cases were classified as intermediate cytogenetic risk group. 16 In our study, karyotype analyses of 57 patients based on classical cytogenetics were available. Normal karyotype was observed in 36 of 57 patients and abnormal karyotype was observed in 21 patients.…”

“…Complete blood count, C-reactive protein, erythrocyte sedimentation rate, PT-aPTT-INR, fibrinogen, D-dimer, biochemical tests such as uric acid and LDH, karyotype analysis, FLT-3, NPM1, t(15;17), t(8;21), inv (16) results were evaluated as laboratory parameters. Time period between diagnosis and induction, whether or not the patient received maintenance treatment and if so, type of maintenance treatment patients have received, responsiveness to induction chemotherapy, number of consolidation chemotherapy cycles the patients received, time of recurrence, whether or not allogeneic bone marrow transplantation was performed, overall survival, and disease-free survival were evaluated.…”